Cell Culture Drug Resistance Testing (CCDRT) Cell Death Assays:

Misconceptions Versus Objective Data

Table of Contents

Introduction
The Modern Empiric Therapy Paradigm
Reasons why ostensibly brilliant people, such as NCI-Designated Cancer Center Directors and NCI Clinical Scientists, know so little about these tests, along with a brief history of cancer "culture and sensitivity" testing.
Data Validating the Biologic and Clinical Utility of CCDRT with Cell Death Assays
Correlations Between Assay Results and Patient Survival
Some Technical Considerations: Frequently Asked Questions
Review of Arguments Offered in Opposition to CCDRT-Directed Chemotherapy
What the Critics Say - The Maurie Markman Editorials
What the Critics Say - THe AMA "Tech Review"
What the Critics Say - The national Blue Shield TEC assesment
What the Critics Say - The Cortazar/Johnson Review
What the Critics Say - The NCI Position on CCDRT
What the Critics Say - The Oncotech Reporter
Cost Benefit Considerations Relevant to Third Party Payment
Concluding Remarks
Bibliography/Citations

(Home Page)